Enalapril for severe congestive heart failure. A double-blind study

Area of Science:

• Cardiology
• Pharmacology

Background:

• Severe cardiac failure poses significant challenges in patient management.
• Existing treatments often require combination therapy.

Purpose of the Study:

• To evaluate the efficacy and safety of enalapril in patients with severe cardiac failure.
• To assess enalapril's effects when co-administered with digoxin and diuretics.

Main Methods:

• Double-blind, parallel, placebo-controlled, randomized trial.
• 12 ambulatory patients with severe cardiac failure.
• Enalapril (MK-421) administered orally, compared against placebo.
• All vasodilator drugs withdrawn prior to the trial.

Main Results:

• Significant improvement in functional class and exercise time (P < 0.01) with enalapril.
• Reduced blood pressure, suggesting afterload reduction.
• Left ventricular ejection fraction remained stable with enalapril, but decreased with placebo (P < 0.001).
• Enalapril was well-tolerated with no apparent adverse effects.

Conclusions:

• Enalapril is effective and well-tolerated for treating severe cardiac failure.
• Enalapril maintains efficacy over 12 weeks when used with digoxin and diuretics.
• Enalapril offers a valuable therapeutic option for severe cardiac failure management.